Two Predictions for the U.S. BioPharma Industry During Trump's 1st 100 DaysThe December 4, 2024, Mar-a-lago meeting with BioPharma execs wasn't about curing cancer. It was about cutting ties with China and pulling the mRNA shots off of the market.December 14, 2024: Greg Hunter and I sat down to discuss December 4, 2024, Mar-a-lago meeting with BioPharma execs and what’s in store for Pfizer and the U.S. BioPharma industry during the first 100 days of the Trump administration after RFK Jr. becomes Secretary of Health & Human Services (HHS). Two (2) Predictions Based on US Law, Government & Industry Reports1. The COVID-19 mRNA Shots Will Be Pulled within Less Than 100 Days
Why Will the COVID-19 Shots Be Pulled Within 100 Days (or less)?
It’s worth investing 55-minutes to watch the full interview on Rumble or USA Watchdog. 2. The BioSecure Act Will Be Passed and Signed into Law by TrumpTrump will not allow US BioPharma companies to continue to partner with Chinese Communist Party (CCP) aligned manufacturers and bet against the US government and American people. US BioPharma ties with China are going to be cut quickly and severely within the 1st 100 days of the administration and Mike Gallagher’s BioSecure Act will be carried through to being signed by Trump by Representative Moolinear and Congress. Why Will BioSecure Act Be Signed into Law by Trump Within 100 Days (or less)?
Watch the Full InterviewIt’s worth investing 55-minutes to watch the full interview on Rumble or USA Watchdog. Greg Hunter is a stellar interviewer and investigative reporter. You can subscribe to his platform for free at USA Watchdog.com Proverbs 21:6-7A fortune made by a lying tongue is a fleeting vapor and a deadly snare. The violence of the wicked will drag them away, for they refuse to do what is right. The Kingston Report. TRUTH WINS.Ways to Support My WorkMail: Karen Kingston/miFight Inc., 960 Postal Way #307, Vista, CA 92081 The Kingston Report is reader-supported. Consider becoming a paid subscriber to support me and my work. You're currently a free subscriber to The Kingston Report. For the full experience, upgrade your subscription. |
No comments:
Post a Comment